Hypoaldosteronism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) |
||
Line 18: | Line 18: | ||
***ACE inhibitors | ***ACE inhibitors | ||
***Angiotensinogen receptor blocker | ***Angiotensinogen receptor blocker | ||
***Potassium sparing diuretics | ***Potassium sparing diuretics | ||
***β-Adrenergic receptor blockers | |||
==References== | ==References== |
Revision as of 14:31, 22 August 2017
Hypoaldosteronism Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hypoaldosteronism secondary prevention On the Web |
American Roentgen Ray Society Images of Hypoaldosteronism secondary prevention |
Risk calculators and risk factors for Hypoaldosteronism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of hypoaldosteronism include:
- Low potassium intake
- Salt intake of 4gm/day
- Avoid drugs affecting the renin angiotensin aldosterone system (RAAS) such as:
- ACE inhibitors
- Angiotensinogen receptor blocker
- Potassium sparing diuretics
- β-Adrenergic receptor blockers